Canada Spends Logo

Explore our Budget 2026 analysis

Grant: Collaborative Research and Development Grants

Université Laval

$41,283.00

Développement de la spectrométrie rétinienne pour l'identification de nouveaux biomarqueurs précoces de la maladie de Parkinson

FY 2019-20

Summary
The regulation of retinal blood flow and oxygenation are recognized as root causes of the majority of ocular diseases, such as glaucoma. There is thus a huge interest in measuring these parameters in vivo, ideally using non-invasive methods. Retnia's technology, based on optical spectroscopy, enables such non-invasive measurements in laboratory and clinical settings. Recently, there has been growing evidence that many neurodegenerative diseases also have an effect on the retina, which is part of the central nervous system. Of the many neurodegenerative diseases that could possibly be sensed in the eye, Parkinson's disease (PD) stands out, due to the retina's similarities to the substantia nigra, a midbrain region that is known to degenerate in PD. PD affects more than 100 000 Canadians and is considered as the second most common neurodegenerative disease. Some disease-modifying treatments exist but drugs that have been tested have provided disappointing results. This can be largely explained by the fact that the cardinal symptoms of PD typically manifest only when more than half of dopaminergic neurons in the substantia nigra are lost. Therefore, early biomarkers of PD are urgently needed to succeed in disease-modifying therapies. In the proposed research project, we will use Retnia's multimodal imaging device to perform spectroscopy on the retina of healthy and parkinsonian monkeys in order to identify and locate optical biomarkers in the form of hemoglobin and melanin retinal content and abnormalities, for early detection of PD.
Program
Collaborative Research and Development Grants
Location
Quebec, Canada
Recipient Type
Academia
Type
Grant
Source
NSERC's Awards Data

As published

Application id
538422-2018
Name nom
Parent, Martin
Department département
Psychiatrie et de neurosciences
Organization id
51
Institution établissement
Université Laval
Province en
Québec
Province fr
Québec
Country en
CANADA
Country fr
CANADA
Fiscal year exercice financier
2019
Competition year année de concours
2018
Award amount
41283
Program id
CRDPJ
Program name en
Collaborative Research and Development Grants
Program name fr
Subventions de recherche et développement coopérative
Group en
RESEARCH PARTNERSHIPS
Group fr
PARTENARIATS DE RECHERCHE
Committee code
96
Committee name en
RPP Internal Decision Cttee
Committee name fr
Cté de décision interne - PPR
Area of application code
1201
Area of application group en
Advancement of knowledge
Area of application group fr
Avancement des connaissances
Area of application en
Life sciences (including biotechnology)
Area of application fr
Sciences de la vie (y compris biotechnologie)
Research subject code
1900
Research subject group en
Biomedical engineering
Research subject group fr
Génie biomédical
Research subject en
Biomedical engineering
Research subject fr
Génie biomédical
Installment
inst:1 - 1
Partie
1
Nb partie
1
Application title
Développement de la spectrométrie rétinienne pour l'identification de nouveaux biomarqueurs précoces de la maladie de Parkinson
Keyword
NSERC
Application summary
The regulation of retinal blood flow and oxygenation are recognized as root causes of the majority of ocular diseases, such as glaucoma. There is thus a huge interest in measuring these parameters in vivo, ideally using non-invasive methods. Retnia's technology, based on optical spectroscopy, enables such non-invasive measurements in laboratory and clinical settings. Recently, there has been growing evidence that many neurodegenerative diseases also have an effect on the retina, which is part of the central nervous system. Of the many neurodegenerative diseases that could possibly be sensed in the eye, Parkinson's disease (PD) stands out, due to the retina's similarities to the substantia nigra, a midbrain region that is known to degenerate in PD. PD affects more than 100 000 Canadians and is considered as the second most common neurodegenerative disease. Some disease-modifying treatments exist but drugs that have been tested have provided disappointing results. This can be largely explained by the fact that the cardinal symptoms of PD typically manifest only when more than half of dopaminergic neurons in the substantia nigra are lost. Therefore, early biomarkers of PD are urgently needed to succeed in disease-modifying therapies. In the proposed research project, we will use Retnia's multimodal imaging device to perform spectroscopy on the retina of healthy and parkinsonian monkeys in order to identify and locate optical biomarkers in the form of hemoglobin and melanin retinal content and abnormalities, for early detection of PD.